guest ::
| Home > Publications database > Subclonal TP53 and KRAS variants combined with poor treatment response identify ultrahigh-risk pediatric patients with T-ALL. > print |
| Home > Publications database > Subclonal TP53 and KRAS variants combined with poor treatment response identify ultrahigh-risk pediatric patients with T-ALL. > print |
| 001 | 299835 | ||
| 005 | 20250318112252.0 | ||
| 024 | 7 | _ | |2 doi |a 10.1182/bloodadvances.2024014209 |
| 024 | 7 | _ | |2 pmid |a pmid:39808796 |
| 024 | 7 | _ | |2 ISSN |a 2473-9529 |
| 024 | 7 | _ | |2 ISSN |a 2473-9537 |
| 037 | _ | _ | |a DKFZ-2025-00572 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kempter, Tamara |b 0 |
| 245 | _ | _ | |a Subclonal TP53 and KRAS variants combined with poor treatment response identify ultrahigh-risk pediatric patients with T-ALL. |
| 260 | _ | _ | |a Washington, DC |b American Society of Hematology |c 2025 |
| 336 | 7 | _ | |2 DRIVER |a article |
| 336 | 7 | _ | |2 DataCite |a Output Types/Journal article |
| 336 | 7 | _ | |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |a Journal Article |b journal |m journal |s 1742216549_25774 |
| 336 | 7 | _ | |2 BibTeX |a ARTICLE |
| 336 | 7 | _ | |2 ORCID |a JOURNAL_ARTICLE |
| 336 | 7 | _ | |0 0 |2 EndNote |a Journal Article |
| 500 | _ | _ | |a #LA:A400# |
| 520 | _ | _ | |a Variations in the TP53 and KRAS genes indicate a particularly adverse prognosis in relapsed pediatric T-cell acute lymphoblastic leukemia (T-ALL). We hypothesized that these variations might be subclonally present at disease onset and contribute to relapse risk. To test this, we examined 2 cohorts of children diagnosed with T-ALL: cohort 1 with 81 patients who relapsed and 79 who matched nonrelapsing controls, and cohort 2 with 226 consecutive patients, 30 of whom relapsed. In cohort 1, targeted sequencing revealed TP53 clonal and subclonal variants in 6 of 81 relapsing patients but none in the nonrelapsing group (P = .014). KRAS alterations were found in 9 of 81 relapsing patients compared with 2 of 79 nonrelapsing patients (P = .032). Survival analysis showed that none of the relapsed patients with TP53 and/or KRAS alterations survived, whereas 19 of 67 relapsed patients without such variants did, with a minimum follow-up time of 3 years (P = .023). In cohort 2, none of the relapsing patients but 10 of 196 nonrelapsing patients carried TP53 or KRAS variants, indicating that mutation status alone does not predict poor prognosis. All 10 nonrelapsing patients with mutations had a favorable early treatment response. Among the total cohort of 386 patients, 188 showed poor treatment response, of whom 69 relapsed. Of these poor responders, 9 harbored TP53 or KRAS variants. In conclusion, subclonal TP53 and KRAS alterations identified at the time of initial diagnosis, along with a poor treatment response, characterize a subset of children with T-ALL who face a dismal prognosis and who may benefit from alternative treatment approaches. |
| 536 | _ | _ | |0 G:(DE-HGF)POF4-311 |a 311 - Zellbiologie und Tumorbiologie (POF4-311) |c POF4-311 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |2 NLM Chemicals |a Tumor Suppressor Protein p53 |
| 650 | _ | 7 | |0 EC 3.6.5.2 |2 NLM Chemicals |a Proto-Oncogene Proteins p21(ras) |
| 650 | _ | 7 | |2 NLM Chemicals |a KRAS protein, human |
| 650 | _ | 7 | |2 NLM Chemicals |a TP53 protein, human |
| 650 | _ | 2 | |2 MeSH |a Humans |
| 650 | _ | 2 | |2 MeSH |a Tumor Suppressor Protein p53: genetics |
| 650 | _ | 2 | |2 MeSH |a Proto-Oncogene Proteins p21(ras): genetics |
| 650 | _ | 2 | |2 MeSH |a Child |
| 650 | _ | 2 | |2 MeSH |a Precursor T-Cell Lymphoblastic Leukemia-Lymphoma: genetics |
| 650 | _ | 2 | |2 MeSH |a Precursor T-Cell Lymphoblastic Leukemia-Lymphoma: mortality |
| 650 | _ | 2 | |2 MeSH |a Precursor T-Cell Lymphoblastic Leukemia-Lymphoma: diagnosis |
| 650 | _ | 2 | |2 MeSH |a Precursor T-Cell Lymphoblastic Leukemia-Lymphoma: therapy |
| 650 | _ | 2 | |2 MeSH |a Male |
| 650 | _ | 2 | |2 MeSH |a Female |
| 650 | _ | 2 | |2 MeSH |a Child, Preschool |
| 650 | _ | 2 | |2 MeSH |a Prognosis |
| 650 | _ | 2 | |2 MeSH |a Adolescent |
| 650 | _ | 2 | |2 MeSH |a Infant |
| 650 | _ | 2 | |2 MeSH |a Mutation |
| 650 | _ | 2 | |2 MeSH |a Treatment Outcome |
| 700 | 1 | _ | |a Richter-Pechańska, Paulina |b 1 |
| 700 | 1 | _ | |a Michel, Katarzyna |b 2 |
| 700 | 1 | _ | |a Rausch, Tobias |b 3 |
| 700 | 1 | _ | |a Erarslan-Uysal, Büşra |b 4 |
| 700 | 1 | _ | |a Eckert, Cornelia |b 5 |
| 700 | 1 | _ | |a Zimmermann, Martin |b 6 |
| 700 | 1 | _ | |a Stanulla, Martin |b 7 |
| 700 | 1 | _ | |a Schrappe, Martin |b 8 |
| 700 | 1 | _ | |a Cario, Gunnar |b 9 |
| 700 | 1 | _ | |a Köhrer, Stefan |b 10 |
| 700 | 1 | _ | |0 0000-0002-9285-6898 |a Attarbaschi, Andishe |b 11 |
| 700 | 1 | _ | |a Korbel, Jan O |b 12 |
| 700 | 1 | _ | |a Kunz, Joachim B |b 13 |
| 700 | 1 | _ | |0 P:(DE-He78)ca062b8db1ee864e03f0a92897728df3 |a Kulozik, Andreas |b 14 |e Last author |u dkfz |
| 773 | _ | _ | |0 PERI:(DE-600)2876449-3 |a 10.1182/bloodadvances.2024014209 |g Vol. 9, no. 6, p. 1267 - 1279 |n 6 |p 1267 - 1279 |t Blood advances |v 9 |x 2473-9529 |y 2025 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:299835 |p VDB |
| 910 | 1 | _ | |0 I:(DE-588b)2036810-0 |6 P:(DE-He78)ca062b8db1ee864e03f0a92897728df3 |a Deutsches Krebsforschungszentrum |b 14 |k DKFZ |
| 913 | 1 | _ | |0 G:(DE-HGF)POF4-311 |1 G:(DE-HGF)POF4-310 |2 G:(DE-HGF)POF4-300 |3 G:(DE-HGF)POF4 |4 G:(DE-HGF)POF |a DE-HGF |b Gesundheit |l Krebsforschung |v Zellbiologie und Tumorbiologie |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0100 |2 StatID |a JCR |b BLOOD ADV : 2022 |d 2024-12-16 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0200 |2 StatID |a DBCoverage |b SCOPUS |d 2024-12-16 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0300 |2 StatID |a DBCoverage |b Medline |d 2024-12-16 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0501 |2 StatID |a DBCoverage |b DOAJ Seal |d 2024-07-05T12:07:28Z |
| 915 | _ | _ | |0 StatID:(DE-HGF)0500 |2 StatID |a DBCoverage |b DOAJ |d 2024-07-05T12:07:28Z |
| 915 | _ | _ | |0 StatID:(DE-HGF)0030 |2 StatID |a Peer Review |b DOAJ : Anonymous peer review |d 2024-07-05T12:07:28Z |
| 915 | _ | _ | |0 StatID:(DE-HGF)0199 |2 StatID |a DBCoverage |b Clarivate Analytics Master Journal List |d 2024-12-16 |
| 915 | _ | _ | |0 StatID:(DE-HGF)1050 |2 StatID |a DBCoverage |b BIOSIS Previews |d 2024-12-16 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0160 |2 StatID |a DBCoverage |b Essential Science Indicators |d 2024-12-16 |
| 915 | _ | _ | |0 StatID:(DE-HGF)1030 |2 StatID |a DBCoverage |b Current Contents - Life Sciences |d 2024-12-16 |
| 915 | _ | _ | |0 StatID:(DE-HGF)1190 |2 StatID |a DBCoverage |b Biological Abstracts |d 2024-12-16 |
| 915 | _ | _ | |0 StatID:(DE-HGF)1110 |2 StatID |a DBCoverage |b Current Contents - Clinical Medicine |d 2024-12-16 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0113 |2 StatID |a WoS |b Science Citation Index Expanded |d 2024-12-16 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0150 |2 StatID |a DBCoverage |b Web of Science Core Collection |d 2024-12-16 |
| 915 | _ | _ | |0 StatID:(DE-HGF)9905 |2 StatID |a IF >= 5 |b BLOOD ADV : 2022 |d 2024-12-16 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0561 |2 StatID |a Article Processing Charges |d 2024-12-16 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0700 |2 StatID |a Fees |d 2024-12-16 |
| 920 | 2 | _ | |0 I:(DE-He78)A400-20160331 |k A400 |l KKE Pädiatrische Leukämie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)A400-20160331 |k A400 |l KKE Pädiatrische Leukämie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)A400-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|